SG11201406582XA - Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the - Google Patents

Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the

Info

Publication number
SG11201406582XA
SG11201406582XA SG11201406582XA SG11201406582XA SG11201406582XA SG 11201406582X A SG11201406582X A SG 11201406582XA SG 11201406582X A SG11201406582X A SG 11201406582XA SG 11201406582X A SG11201406582X A SG 11201406582XA SG 11201406582X A SG11201406582X A SG 11201406582XA
Authority
SG
Singapore
Prior art keywords
spirox
methylene
methyl
intrauterine
systems
Prior art date
Application number
SG11201406582XA
Other languages
English (en)
Inventor
Norbert Schmees
Lars Röse
Tuula Valo
Katja Prelle
Reinhard Nubbemeyer
Henriikka Korolainen
Harri Jukarainen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48142002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201406582X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201406582XA publication Critical patent/SG11201406582XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201406582XA 2012-04-23 2013-04-19 Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the SG11201406582XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012206652 2012-04-23
PCT/EP2013/058220 WO2013160213A1 (de) 2012-04-23 2013-04-19 INTRAUTERINE ANWENDUNG VON 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONEN, INTRAUTERINE SYSTEME ENTHALTEND 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONE, SOWIE DEREN VERWENDUNG IN DER KONTRAZEPTION UND GYNÄKOLOGISCHEN THERAPIE

Publications (1)

Publication Number Publication Date
SG11201406582XA true SG11201406582XA (en) 2014-11-27

Family

ID=48142002

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406582XA SG11201406582XA (en) 2012-04-23 2013-04-19 Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the

Country Status (28)

Country Link
US (1) US20150065472A1 (de)
EP (1) EP2841074A1 (de)
JP (1) JP2015514791A (de)
KR (1) KR20150004807A (de)
CN (1) CN104254333A (de)
AR (1) AR090799A1 (de)
AU (1) AU2013254840A1 (de)
BR (1) BR112014026193A2 (de)
CA (1) CA2871003A1 (de)
CL (1) CL2014002836A1 (de)
CO (1) CO7111255A2 (de)
CR (1) CR20140490A (de)
CU (1) CU20140121A7 (de)
DO (1) DOP2014000241A (de)
EA (1) EA201491922A1 (de)
EC (1) ECSP14024250A (de)
HK (1) HK1205000A1 (de)
IL (1) IL235095A0 (de)
IN (1) IN2014DN07839A (de)
MA (1) MA37444A1 (de)
MX (1) MX2014012849A (de)
PE (1) PE20142438A1 (de)
PH (1) PH12014502372A1 (de)
SG (1) SG11201406582XA (de)
TN (1) TN2014000444A1 (de)
TW (1) TW201350122A (de)
UY (1) UY34758A (de)
WO (1) WO2013160213A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015055789A1 (en) * 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90627C (fi) 1992-07-31 1994-03-10 Leiras Oy Laitteisto lääkeainesauvan varustamiseksi vaipalla
PH30867A (en) 1992-07-31 1997-12-09 Leiras Oy Method and equipment for installing a medicine capsule on a support.
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
PL201878B1 (pl) * 2000-01-18 2009-05-29 Bayer Schering Pharma Ag Kompozycja farmaceutyczna w doustnej postaci dawkowania. zawierająca estrogen i drospirenon, zastosowanie kompozycji i preparat farmaceutyczny
CA2771944A1 (en) * 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
DE102007063495A1 (de) * 2007-12-29 2009-09-17 Bayer Schering Pharma Aktiengesellschaft 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel
DE102007063496A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
EP2140860A1 (de) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy Verbessertes Verhütungsverfahren
PT2012063262W (pt) * 2010-11-08 2015-06-11 Hll Lifecare Ltd Um novo dispositivo intra-uterino com libertação controlada de cobre

Also Published As

Publication number Publication date
AR090799A1 (es) 2014-12-10
EP2841074A1 (de) 2015-03-04
BR112014026193A2 (pt) 2017-06-27
TN2014000444A1 (en) 2016-03-30
WO2013160213A1 (de) 2013-10-31
UY34758A (es) 2013-11-29
PE20142438A1 (es) 2015-02-01
US20150065472A1 (en) 2015-03-05
ECSP14024250A (es) 2015-12-31
HK1205000A1 (en) 2015-12-11
MX2014012849A (es) 2015-02-05
CL2014002836A1 (es) 2015-03-13
TW201350122A (zh) 2013-12-16
CU20140121A7 (es) 2014-12-26
IL235095A0 (en) 2014-12-31
CN104254333A (zh) 2014-12-31
CO7111255A2 (es) 2014-11-10
MA37444A1 (fr) 2016-11-30
PH12014502372A1 (en) 2015-01-26
KR20150004807A (ko) 2015-01-13
CR20140490A (es) 2014-11-17
DOP2014000241A (es) 2014-12-31
IN2014DN07839A (de) 2015-04-24
EA201491922A1 (ru) 2015-04-30
CA2871003A1 (en) 2013-10-31
JP2015514791A (ja) 2015-05-21
AU2013254840A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
EP3035813A4 (de) Verdampfer
EP3036248A4 (de) Nukleotidanaloga
IL236463A0 (en) Bifluorodioxalan-amino-benzaimidazole compounds, preparations containing them, methods for their production and their uses
EP2826473A4 (de) Neuartige verwendung von patchoulol
EP3042672A4 (de) Blutreiniger
EP2935168A4 (de) Synthese von 3,3,3-trifluorpropyn
HK1212986A1 (zh) 作為 -抑制劑的苯基乙基吡啶衍生物
EP3045222A4 (de) Reaktor
EP3015164A4 (de) Reaktor
EP2903614A4 (de) Neuartige verbindungen, deren synthese und deren verwendungen
GB201213171D0 (en) Braking systems
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
SG11201500119QA (en) Deluge system
EP2903979A4 (de) Neuartige verbindungen, deren herstellung und verwendung
ZA201504003B (en) Stabilizing system
HK1207317A1 (en) Substituted 1,6-naphthyridines 16-
GB2511381B (en) Clasp system
IL280316B (en) Amphiphilic compounds, preparations and their use
IL237542B (en) Amphiphilic compounds, their preparations and uses
PL2964607T3 (pl) Sposób wytwarzania halogeno-n,n-dimetylobenzyloamin
GB201305858D0 (en) Catalyst composition
IL237540A0 (en) Amphiphilic compounds, their preparations and uses
IL237538B (en) Amphiphilic compounds, their preparations and uses
SG11201406582XA (en) Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the
IL237539A0 (en) Amphiphilic compounds, their preparations and uses